GHRP-2 Pralmorelin

Pralmorelin is an orally-active, synthetic peptide drug, specifically, an analogue of met-enkephalin, with the amino acid sequence D-Ala-D-(β-naphthyl)-Ala-Ala-Trp-D-Phe-Lys-NH2. It acts as a ghrelin/growth hormone secretagogue receptor (GHSR) agonist, and was the first of this class of drugs to be introduced clinically. Acute administration of the drug markedly increases the levels of plasma growth hormone (GH) and reliably induces sensations of hunger and increases food intake in humans.
Pralmorelin was also under investigation for the treatment of GHD and short stature (pituitary dwarfism), and made it to phase II clinical trials for these indications, but was ultimately never marketed for them. This may be because the ability of pralmorelin to increase plasma GH levels is significantly lower in people with GHD relative to healthy individuals.

Properties
Density: 1.27 g/cm3
Boiling Point: 1265.3ºC at 760 mmHg
Flash Point: 719ºC
Refractive Index: 1.638
Vapor Pressure: 0mmHg at 25°C

Related Prodcuts:

Tripeptide-1; Prezatide copper acetate; Tetrapeptide-30; Myristoyl tetrapeptide-12; Pentapeptide-3; Melitane Nonapeptide-1; Decapeptide-12; Acetyl tetrapeptide-3; Syn-Ake acetate; GHRP-6

1: Nasu R, Kumagai Y, Kogetsu H, Tsujimoto M, Ohtani H, Sawada Y. Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats. Drug Metab Dispos. 2005 Oct;33(10):1488-94. Epub 2005 Jul 20. PubMed PMID: 16033952.

2: Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs R D. 2004;5(4):236-9. Review. PubMed PMID: 15230633.